Omeros (NASDAQ:OMER) Now Covered by HC Wainwright

HC Wainwright began coverage on shares of Omeros (NASDAQ:OMER - Free Report) in a research note published on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $9.00 target price on the biopharmaceutical company's stock. HC Wainwright also issued estimates for Omeros' Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.78) EPS and FY2026 earnings at ($1.14) EPS.

Other analysts have also issued reports about the company. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a report on Friday, May 16th. Wall Street Zen downgraded Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 6th. Finally, D. Boral Capital restated a "buy" rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Omeros presently has an average rating of "Moderate Buy" and a consensus target price of $18.00.

Omeros Trading Down 4.2%

Shares of OMER traded down $0.15 during trading hours on Tuesday, reaching $3.40. The stock had a trading volume of 696,461 shares, compared to its average volume of 688,448. The company has a market capitalization of $199.22 million, a price-to-earnings ratio of -1.47 and a beta of 2.20. The firm has a 50-day simple moving average of $5.16 and a 200 day simple moving average of $7.80. Omeros has a 12 month low of $2.97 and a 12 month high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). On average, equities analysts forecast that Omeros will post -3.09 EPS for the current year.

Hedge Funds Weigh In On Omeros

A number of hedge funds and other institutional investors have recently modified their holdings of OMER. Nomura Holdings Inc. lifted its holdings in Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock worth $7,383,000 after acquiring an additional 430,932 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in shares of Omeros during the 4th quarter worth $1,488,000. Wellington Management Group LLP bought a new stake in shares of Omeros during the 1st quarter worth $1,118,000. Nuveen LLC purchased a new position in shares of Omeros in the 1st quarter worth about $938,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Omeros during the fourth quarter valued at about $1,120,000. Hedge funds and other institutional investors own 48.79% of the company's stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.